MUC1 and breast carcinoma: A pilot Phase III trial of oxidized mannan-MUC1 (5 TR) in stage II breast cancer patients reported a recurrence rate of 12.5% (2 of 16) in patients receiving mannan-MUC1 vs. 60% (9 of 15) for placebo in a 15-year follow-up [20].